Ensysce Biosciences Announces 1-for-15 Reverse Stock Split
Portfolio Pulse from
Ensysce Biosciences, a clinical-stage pharmaceutical company, will implement a 1-for-15 reverse stock split on December 6, 2024. This move is aimed at consolidating shares to potentially increase the stock price.

December 03, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ensysce Biosciences will execute a 1-for-15 reverse stock split on December 6, 2024, which may affect its stock price and market perception.
The reverse stock split will reduce the number of shares outstanding, which can lead to an increase in the stock price if the market perceives it positively. However, reverse splits can also be seen as a sign of financial distress, leading to mixed investor reactions.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100